Regeneron Pharmaceuticals Suffers Worst Month in Two Years …
WEB8 hours ago · At BMO Capital Markets, analyst Evan Seigerman pointed out that the denial of Regeneron’s motion for a preliminary injunction isn’t the end of the road in the patent infringement case.
Buy Rating Affirmed: Regeneron’s Growth Potential Anchored by …
WEBSep 17, 2024 · Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Regeneron (REGN – Research Report) and keeping the price target at $1,300.00. Evan Seigerman has given his Buy rating due...
GLP-1 demand is going to remain higher than supply for ... - CNBC
WEB3 days ago · Evan Seigerman, BMO senior analyst, joins 'Closing Bell Overtime' to talk today's Capitol Hill hearing with Novo Nordisk's CEO and the demand for weight-loss drugs.
Buy Rating Affirmed for AbCellera Biologics Amid Positive TCE …
WEBJan 11, 2024 · BMO Capital analyst Evan Seigerman has reiterated their bullish stance on ABCL stock, giving a Buy rating on January 5. Evan Seigerman has given his Buy rating due to a combination of factors...
Eli Lilly’s Kisunla Approval Spurs Buy Rating Amid Anticipated …
WEBJul 3, 2024 · Evan Seigerman has given his Buy rating due to a combination of factors related to Eli Lilly & Co’s recent developments in their pharmaceutical offerings, particularly the approval of their...
Structure Therapeutics Stock Could Rocket 87% Higher, According …
WEBJun 11, 2024 · Encouraging phase 2 results convinced Evan Seigerman at BMO Capital Markets to raise his price target on the stock to $100 per share. The new target implies an 87% gain from recent prices.
Eli Lilly lifts guidance after sales of Mounjaro and Zepbound drugs …
WEBApr 30, 2024 · Evan Seigerman, an analyst at BMO Capital Markets, said in a note that “the majority of this miss was due to a lack of supply, with Lilly likely shifting capacity to Zepbound during . . .
Eli Lilly's GLP-1 demand drives up stock price post Q1 results
WEBApr 30, 2024 · BMO Capital Markets BioPharma Equity Research Managing Director Evan Seigerman joins the Morning Brief to discuss the stock's outlook. Seigerman notes that "demand is off the charts" for the...
BMO Capital Markets Focused on Expanding Healthcare Franchise
WEBNEW YORK, June 22, 2021 /CNW/ - BMO Capital Markets, the investment & corporate banking arm of BMO Financial Group (NYSE: BMO) (TSX: BMO), today announced that it has hired Evan Seigerman as a Managing Director and Senior Equity Research Analyst covering the biotechnology and pharmaceutical industries.
Analyst says these are the 'critical' next steps for Eli Lilly
WEBFeb 6, 2024 · Evan Seigerman, BMO Capital Markets Managing Director joins Yahoo Finance Live, saying he continues to be "surprised at the demand" for these drugs.
- Some results have been removed